Velocity Clinical Research
JUNE 27, 2023
Rosenstock is the lead investigator for Novo Nordisk’s ONWARDS 1 program exploring the first investigational once-weekly insulin. “In In ONWARDS 1, insulin icodec allowed people to spend significantly more Time in Range, with comparable Time below Range vs. once-daily basal insulin glargine U100,” said Dr. Rosenstock. “A
pharmaphorum
JUNE 14, 2021
This can lead to metabolic abnormalities including insulin resistance, diabetes, and elevated levels of blood lipids (such as high cholesterol). Eventually it was bought by Amryt who, keen to get the drug licensed, resubmitted it to NICE in 2020.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 1, 2020
The first was insulin – Frederick Banting and colleagues managed to isolate insulin that could treat diabetes, up until that point a fatal condition. The period between 1918 and 1939 was marked by two breakthroughs that presaged the arrival of the pharma industry as we know it today.
XTalks
SEPTEMBER 17, 2020
While clinical researchers occasionally need to identify and validate a new surrogate endpoint for a given trial, choosing endpoints that have been previously used as the basis of NDAs and BLAs can clear the path to eventual approval. What Is a Surrogate Endpoint?
Expert insights. Personalized for you.
52 
Let's personalize your content